Frances Ferguson, MD
Internal Medicine · Newton, GANPI 1174750988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,479 of the $80,360 with a category attached, or 62.8%. Pfizer accounts for 94.1% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $27,410, 3.7 times the $7,427 reported in 2019. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $511.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$76K
- Sanofi Pasteur Inc.$3K
- Novo Nordisk$418
- Lilly USA, LLC$207
- Organogenesis Inc.$122
- Johnson & Johnson$107
- plus $450 from 11 others
What the payments were for
- Consulting fees$12,54516%
- Speaking & faculty fees$50,47963%
- Travel & lodging$14,43418%
- Food & beverage$2,9014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 109 | $75,619 |
| Sanofi Pasteur Inc. | 2 | $3,436 |
| Novo Nordisk | 11 | $418 |
| Lilly USA, LLC | 11 | $207 |
| Organogenesis Inc. | 1 | $122 |
| Johnson & Johnson(2 entities) | 2 | $107 |
| Bayer | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| GSK | 3 | $56 |
| Acadia Pharmaceuticals Inc | 2 | $49 |
| UCB, Inc. | 1 | $49 |
| Boston Scientific | 1 | $30 |
| Exact Sciences | 1 | $29 |
| AstraZeneca | 2 | $26 |
| Seqirus USA Inc | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR 20$47,918
- PREVNAR - 13$9,800
- ABRYSVO$7,806
- COMIRNATY$6,053
- PuraPly$122
How this compares
$80,360 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $133,756 |
| OzempicSemaglutide | 70 | $87,127 |
| FarxigaDapagliflozin Propanediol | 64 | $78,370 |
| MounjaroTirzepatide | 46 | $54,649 |
| EliquisApixaban | 47 | $48,597 |
| TrulicityDulaglutide | 39 | $36,173 |
| LinzessLinaclotide | 40 | $35,048 |
| MyrbetriqMirabegron | 45 | $31,943 |
| JanuviaSitagliptin Phosphate | 22 | $29,799 |
| RybelsusSemaglutide | 16 | $23,843 |
| EntrestoSacubitril/Valsartan | 25 | $22,835 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $22,149 |
| XareltoRivaroxaban | 15 | $18,588 |
| TradjentaLinagliptin | 15 | $16,695 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $12,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $418 | $110,97086 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $207 | $92,79897 claims |
| AstraZenecaFarxiga, Symbicort | $26 | $89,00296 claims |
| PfizerEliquis | $75,619 | $48,59747 claims |
| GSKTrelegy Ellipta | $56 | $22,14927 claims |
| Johnson & JohnsonXarelto | $107 | $18,58815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Newton
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.